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We previously hypothesized that a lipoglycan of Bifidobacterium bifidum subsp. pennsylvanicum cross-reacts
with the Platelia Aspergillus (PA) enzyme-linked immunosorbent assay (ELISA) based on the presence of
galactofuranosyl epitopes in the cell wall (M. A. S. H. Mennink-Kersten, R. R. Klont, A. Warris, H. J. M. Op
den Camp, and P. E. Verweij, Lancet 363:325–327, 2004). We tested this hypothesis by testing bacterial
suspensions of different bifidobacterial species and other gram-positive and -negative bacteria with the PA
ELISA, which is used to detect circulating galactomannan for the serodiagnosis of invasive aspergillosis.
Furthermore, neonatal fecal samples were enumerated for bifidobacteria by fluorescence in situ hybridization
(FISH) and tested for PA ELISA reactivity. All bifidobacteria, except B. infantis and B. adolescentis, showed
reactivity 6- to 600-fold higher compared to the controls (i.e., Micrococcus luteus and Propionibacterium freuden-
reichii, which contain a cell wall lipomannan). Eggerthella lenta showed a 25-fold-higher reactivity. ELISA
reactivity was clearly shown to be associated with bacterial lipoglycans containing a -1,5-galactofuranosyl
chain. All neonatal feces showed PA ELISA reactivity and associated numbers of bifidobacteria. Since high
concentrations of bifidobacteria are present in the human gut, these bacteria or excreted lipoglycan may cause
false serum PA ELISA reactivity in selected patient groups, especially neonates.
Invasive aspergillosis (IA) has become a leading cause of
death among immunocompromised patients. A commercial
sandwich enzyme-linked immunosorbent assay (ELISA)
(Platelia Aspergillus [PA] ELISA; Bio-Rad, Marnes-la-Co-
quette, France) that is widely used as a diagnostic tool in
centers throughout the world detects a fungal antigen which is
present in body fluids of patients with IA (5, 24, 44). The PA
ELISA specifically detects circulating galactomannan (GM), a
cell wall polysaccharide secreted by Aspergillus, by using the
immunoglobulin M (IgM) monoclonal antibody EB-A2 as cap-
tor and detector (44). This EB-A2 binds to the -1,5-linked
galactofuranosyl (Galf) chain of the GM molecule (45) and
possibly to other fungal Galf-containing antigens that circulate
in sera of patients infected with aspergillus (22, 27).
A major difficulty in the serodiagnosis of IA is the occur-
rence of false-positive PA ELISA results, which varies from
5% in adults to as much as 83% in neonates in consecutive
serum samples (38, 42, 46). At present no valid explanation has
been found although several theories have been postulated.
Cross-reactivity of the IgM monoclonal antibody with other
molecules present in serum might occur although this could
not be documented with blood products and antigens from
bacteria that cause bacteremia (47). Cross-reactivity has been
reported in vitro with the GM from Penicillium or Paecilomyces
spp., but these molds very rarely cause invasive infection in
humans (47). Besides resulting from IA, circulating Aspergillus
GM could result from massive colonization of the gastrointes-
tinal tract by Aspergillus (39) or from foods that are contami-
nated with Aspergillus (4) or contain its GM (1, 10). This fecal
GM may reach the circulation in patients with dysfunction of
the intestinal mucosal barrier. Furthermore, intravenous ad-
ministration of the antibiotics piperacillin-tazobactam and
amoxicillin-clavulanic acid, which show in vitro PA reactivity,
has been shown to cause serum PA ELISA reactivity in pa-
tients without evidence of IA (26, 52). This PA reactivity is
probably due to GM that originates from Penicillium that is
used for antibiotic production (51).
After a review of the literature for microorganisms that
contain galactofuranoses, it was found that a membrane-asso-
ciated molecule of Bifidobacterium bifidum subsp. pennsylvani-
cum contained a terminal linear polysaccharide of more than
seven -1,5-linked Galf residues which mimics the epitope
recognized by EB-A2 (7). It was suggested that lipoteichoic
acid (LTA)-like amphiphiles of bifidobacterial species might
cause PA ELISA reactivity in neonates after translocation be-
cause of the immaturity of the intestinal mucosa (28). In ad-
dition, Bifidobacterium species are members of the normal
gastrointestinal microflora of humans, comprising up to 6% of
the total fecal microflora of adults and up to 91% and 75% of
the total fecal microflora in breast-fed and formula-fed infants,
respectively (15, 37).
LTAs represent a group of structurally related lipid macro-
amphiphiles which are hydrophobically anchored to the cyto-
plasmic membrane, while the hydrophilic chain (mostly poly-
glycerophosphate) penetrates the peptidoglycan network and
may be detectable as a surface antigen (Fig. 1) (54). In the
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high-GC subdivision of gram-positive bacteria, LTAs are
functionally replaced by lipoglycans, which contain a linear or
branched polysaccharide as a hydrophilic moiety; this polysac-
charide may carry monoglycerophosphate side chains (Bi-
fidobacterium species) or succinyl esters (lipomannan from Mi-
crococcus, Mycobacterium, or Propionibacterium) (9). The
macroamphiphiles are secreted even during normal growth
both with and without their lipid anchor. Secretion is stimu-
lated by exposure to -lactam antibiotics (9, 12, 33, 35). In
aqueous solutions, the acylated molecules form micellar aggre-
gates (53).
The aim of our research was to test the in vitro reactivity of
different bacteria including bifidobacterial species and other
members of the gut microflora of humans with the PA ELISA.
Any reactivity was correlated with the presence and structure
of bacterial lipid macroamphiphiles based on review of the
literature.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Reactivity with the PA ELISA was
investigated in vitro by testing cell suspensions of a range of bacteria, including
11 bifidobacterial species and 15 other bacteria (gram-positive and -negative
species), most known to be common inhabitants from the human gut (Table 1).
For each bacterium the structure of the lipid macroamphiphile was documented
based on review of the literature (7–9, 13, 16, 18, 30, 48). Bacteria were cultured
anaerobically (80% N2, 10% CO2, 10% H2) on agar plates containing fastidious
anaerobic agar (Lab M) or aerobically on Columbia agar (BBL), at 37°C. B.
bifidum subsp. pennsylvanicum was also cultured on reinforced clostridial me-
dium (RCM; Oxoid). Because this liquid medium showed ELISA reactivity, it
was hydrolyzed with acid (pH 2 with HCl for 3 h at 100°C) and neutralized with
NaOH at pH 6.8 before inoculation. Acid hydrolysis removes Galf chains that are
present in the RCM, which originate from contaminated medium components
like meat extracts.
Fecal sample collection and FISH analysis. Fecal samples from nine healthy
neonates were obtained. Babies were fully breast-fed or formula fed and ranged
in age from 3 days to 4.5 months. No baby had been on antibiotic treatment prior
to fecal sampling. Fecal samples were stored at 80°C until shipment on dry ice
to Groningen for fluorescence in situ hybridization (FISH) analysis. Samples
were processed and FISH analysis was performed as described by Harmsen et al.
(14). The bifidobacterial probe Bif164 (21), a 16S rRNA-based oligonucleotide
probe, was used to enumerate total bifidobacteria in the fecal samples.
PA ELISA. Bacterial cells were scraped of the agar plates and suspended in
0.9% NaCl (wt/vol). Fresh fecal samples were suspended in saline to give a final
concentration of 100 mg/ml (wet weight). The complete mixtures were serial
diluted and used for detection of reactivity by the PA ELISA. The PA ELISA
was performed according to the manufacturer’s instructions. However, the pre-
treatment step intended to dissociate immune complexes was omitted, except for
the R3, R4, and R5 calibration samples (serum spiked with GM) and the fecal
samples. Briefly, 50 l of a reaction mixture containing horseradish peroxidase-
conjugated anti-GM monoclonal antibody EB-A2 was added to each well of a
microtitration plate coated with the same monoclonal antibody EB-A2, followed
by addition of 50 l of the bacterial cell suspension or pretreated sample. After
90 min of incubation at 37°C, the plates were washed five times with washing
buffer before 200 l of buffer containing tetramethylbenzidine solution was
added. Then the plates were incubated for another 30 min in the dark at room
temperature, followed by the addition of 100 l of 1.5 N sulfuric acid to stop the
reaction. The optical density (OD) was read at 450 and 620 nm. A test sample
was considered positive when the OD at 450 nm was higher than the cutoff
sample (i.e., 1.0 ng GM). Pretreatment of the R3, R4, and R5 calibration samples
and the fecal samples was done by mixing 300 l of each sample with 100 l of
treatment solution (4% EDTA), and the mixture was subsequently boiled for 5
min. After centrifugation (10,000  g, 10 min), the supernatant was used for
further testing.
All bacterial isolates were tested twice and in duplicate. In vitro reactivity was
quantified as ELISA index (EI) correlated to the total protein content of the
tested cell suspension. Total protein concentrations were determined with a
protein assay kit (Bio-Rad, Richmond, CA), with bovine -globulin as a stan-
dard, after boiling the cells for 15 min in 1 M NaOH and neutralizing with 1 M
HCl. The reactivity of Micrococcus luteus and Propionibacterium freudenreichii,
which are known to have a lipomannan in the cell wall (9), served as negative
controls. Furthermore, 1 ng/ml of purified GM (22) was added to M. luteus
samples with different total protein contents. Fecal samples were tested twice,
and in vitro reactivity was expressed as EI per gram of feces.
Cell count. Direct microscopic counts of tested bacterial cell samples were
obtained by using duplicate smears of 0.01 ml of a 102-fold dilution spread over
1 cm2 of a glass slide. The smears were heat fixed and gently Gram stained. Ten
fields were counted, and the counts were then correlated with the actual sample
size.
Preparation and deacylation of cell extracts and cell pellet samples. After
growth of B. bifidum subsp. pennsylvanicum on liquid RCM, samples were taken
for PA ELISA. Part of the culture (1-ml samples) was centrifuged at 8,000  g
(10 min, room temperature) followed by filtration of the supernatant (0.2 m).
The clear supernatant was used as a cell-free culture fluid. The cell pellet was
suspended in 200 l 0.9% NaCl. The supernatant and suspended-pellet samples
were serially diluted and analyzed for PA ELISA reactivity and compared with
the total culture sample. Diluted samples were also deacylated by treatment with
0.1 M NaOH in ethanol for 30 min at 37°C as described before (34).
RESULTS
ELISA reactivities of different bacterial samples. B. bifidum
subsp. pennsylvanicum bacterial suspensions showed reactivity
when tested in the PA ELISA. Reactivity was tested with a
range of sample dilutions and showed saturation kinetics (Fig.
FIG. 1. Diagrammatic representation of a generalized gram-posi-
tive cell wall-plasma membrane complex. Pr, protein; PL, phospholip-
ids; GL, glycolipid; Ps, polysaccharide; aLTA, acetylated lipoteichoic
acid; dLTA, deacetylated lipoteichoic acid; tLTA, lipoteichoic acid
molecules in the process of excretion. M1, M2, and M3 are various
micellar complexes present in the external milieu. (Adapted from
reference 54 with permission of the publisher.)
3926 MENNINK-KERSTEN ET AL. J. CLIN. MICROBIOL.
 o
n
 July 11, 2012 by Universiteitsbibliotheek
http://jcm.asm.org/
D
ow
nloaded from
 
2). Reactivity was determined in the linear part of the graph
and was expressed as EI per milligram of protein. Protein
concentrations of the undiluted samples ranged from 0.1 to 0.5
mg/ml. Some cell samples reacted so strongly that even a 40-
fold dilution gave a positive PA ELISA result (EI  1.0) as
shown for Bifidobacterium lactis (Fig. 2). The reactivity of all
tested bacteria is shown in Fig. 3. Most bifidobacteria (from
human, animal, or food origin) showed cross-reactivity with the
PA ELISA. Reactivities ranged from 6-fold (Bifidobacterium
breve) to 600-fold (B. lactis) higher than the controls. Some of
these species are known to contain a lipoglycan with more than
7 -1,5-linked Galf residues (B. bifidum, B. breve, and Bi-
fidobacterium longum; Table 1). Bifidobacterium infantis and
Bifidobacterium adolescentis, which do not seem to have -1,5-
FIG. 2. PA EI related to the protein concentration of the total
bifidobacterial cell sample. F, B. bifidum subsp. pennsylvanicum; ■, B.
lactis. The detection limit of the assay is indicated as a dotted line.
TABLE 1. Origin and characteristics of tested bacterial species and strains
Bacterial species Strain or sourcea Origin Characteristics Reference(s)
Bifidobacterial species
B. adolescentis ATCC 15703 Human intestine Soluble polysaccharide without -1,5-Galf 16
B. animalis Winclove 53 Fermented milk Lipoglycan
CUETM 89/13 Rat feces
B. bifidum CUETM 89/27 Breast-fed neonate intestine Lipoglycan with 11–18 -1,5-Galf residues 7, 18
Winclove 1 Human intestine
subsp. pennsylvanicum DSM20239 Human intestine
B. breve Winclove 9 Not specified
Gavini crohn 16 Neonate intestine Lipoglycan with 11–18 -1,5-Galf residues 18
ATCC 15700 Neonate intestine
B. catenulatum CUETM 89/96 Human intestine Cell wall polysaccharide with 1 internal
-1,5-Galf residue
30
CUETM 89/29 Human intestine
B. dentium CUETM 89/20 Dental carries Lipoglycan
B. infantis ATCC 15697 Infant intestine Cell wall polysaccharide with 1 internal
-1,3-Galf residue
48
B. lactis Winclove 18 Fermented milk Lipoglycan
B. longum Winclove 3 Not specified Lipoglycan with 11–18 -1,5-Galf residues 18
Winclove 16 Not specified
Gavini BS 175 Neonate intestine
B. pseudocatenulatum Gavini BS 82 Human intestine Lipoglycan
B. pseudolongum
subsp. pseudolongum Gavini MB7 Animal feces Lipoglycan
subsp. globosum Gavini RU 224 Animal feces Lipoglycan
Other gram-positive bacteria
Actinomyces viscosus AZN Human infection Lipoglycan
Bacillus subtilis AZN Human infection LTA 8
Clostridium perfringens ATCC 13124 Not specified LTA 13
Enterococcus faecalis ATCC 29212 Urine LTA 8
Eggerthella lenta ATCC 25559 Rectal tumor Lipoglycan
Lactobacillus acidophilus AZN Human infection LTA
Lactobacillus casei AZN Human infection Unglycosylated LTA 8
Listeria monocytogenes AZN Human infection LTA with Galp monomeric residues 8
Micrococcus luteus AZN Human infection Lipomannan 9
Nocardia farcinica AZN Human infection Lipoglycan
Propionibacterium acnes ATCC 6919 Facial acne Lipoglycan
Propionibacterium freudenreichii ATCC 6207 Dairy Lipomannan 9
Staphylococcus epidermidis ATCC 12228 Not specified LTA
Streptococcus pyogenes ATCC 43202 Not specified Unglycosylated LTA 8
Gram-negative bacteria
Bacteroides fragilis AZN Human infection LPS
Escherichia coli ATCC 25022 Human infection LPS
Klebsiella pneumoniae ATCC 27736 Human infection LPS with 1 internal -1,3-Galf residue
Pseudomonas aeruginosa ATCC 10145 Not specified LPS
a CUETM, Collection de 1’Unite´ d’Ecotoxicologie Microbienne, Institut National de la Sante´ et de la Recherche Me´dicale, 59651 Villeneuve d’Ascq, France; DSM,
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1B, D-38124 Braunschweig, Germany; Gavini, strains received from F. Gavini,
INRA, Villeneuve d’Ascq, France; Winclove, Collection from Winclove BioIndustries BV, P.O. Box 37239, 1030 AE Amsterdam, The Netherlands; AZN, Collection
of the Department of Medical Microbiology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
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linked Galf residues in their cell wall, showed low reactivity.
Furthermore, other gram-positive bacteria containing LTA or
lipoglycan showed low reactivity, including the negative con-
trols containing a lipomannan. Gram-negative bacteria con-
taining lipopolysaccharide (LPS) also reacted negatively. The
only nonbifidobacterial species that showed PA ELISA reac-
tivity was Eubacterium lentum. This species, which is one of the
predominant microorganisms from the human intestine, has
been reclassified as Eggerthella lenta (19). In contrast to other
eubacteria, which belong to the low-GC group, this bacte-
rium has a high GC content and by definition a lipoglycan
instead of an LTA (31).
PA ELISA reactivity per gram of feces. Table 2 shows a
calculation of the EI per gram of neonatal feces for the most
frequently found bifidobacterial species, i.e., B. longum, B.
bifidum, and B. breve. Matsuki et al. (25) studied the distribu-
tion of bifidobacterial species in the intestinal tract with 16S
rRNA gene-targeted species-specific primers and found about
one to three species per neonate (25). The EI was corrected for
the dilution factor. This reactivity was then correlated to the
FIG. 3. Cross-reactivity of different bacterial species and strains with the PA ELISA. Reactivity is quantified as EI correlated to the total protein
content of the cell suspension tested. Black bars indicate the control samples. Total protein contents of cell samples ranged from 0.1 to 0.5 mg/ml.
Control samples include 1 ng/ml GM (clinical cutoff value) added to M. luteus samples with different total protein contents.
TABLE 2. Calculated and measured PA ELISA reactivity per gram of neonatal feces
Tested sample Occurrence(%)a
EI  dilution
factor
No. of
cells (107)b
No. present in feces
g1 EI g feces
1
B. longum 37 80.7 1.0 109.8–10.1c 51,000–102,000
B. bifidum 22 10.2 0.7 1010.3c 29,000
B. breve 70 4.8 3.8 1010.5–10.7c 4,000–6,000
Fecal samples from neonates
1 5.6 1.40  107d 1,120
2 72.0 1.90  107d 14,400
3 1.0 2.50  109d 200
4 11.5 1.20  107d 2,300
5 181.6 3.00  109d 36,320
6 54.8 1.90  107d 10,960
7 125.8 3.60  109d 25,160
8 45.1 2.10  109d 9,020
9 57.6 5.10  109d 11,520
a Expressed as % of the total number of fecal samples that were tested, taken from reference 25.
b Present in 50 l undiluted cell sample.
c Taken from reference 29.
d Determined by FISH analysis.
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number of cells present in 50 l undiluted cell sample. So
knowing the reactivity per cell, the reactivity per gram of feces
can be calculated by multiplying it with the amount of cells
present per gram of feces. These fecal numbers were taken
from the literature but may vary depending on the method
used for quantification (15, 29). Table 2 also shows the EI per
gram of feces as measured in the nine collected neonatal fecal
samples. All fecal samples exhibited PA ELISA reactivity. Fur-
thermore, all fecal samples contained bifidobacterial species as
determined by FISH.
ELISA reactivity of liquid cultures. The result of the ELISA
reactivity of the B. bifidum subsp. pennsylvanicum RCM cul-
tures is shown in Table 3. When the undiluted total cell culture
was tested in the PA ELISA, no reactivity was observed. How-
ever, 40-fold dilution of the samples gave a positive reaction
(EI 	 1.553). Part of this reactivity was associated with the
cells (25.8%) and another part (37.8%) with secreted products.
Blank media showed no reactivity. Deacylation of the same
samples completely removed ELISA reactivity in contrast to
deacylation of GM samples containing 1.5, 3, and 5 ng GM
(purified GM was a kind gift from Marc Tabouret, Bio-Rad,
Steenvoorde, France) per ml water, which showed a 50% de-
crease in reactivity upon this treatment (results not shown).
DISCUSSION
Most bifidobacteria showed significant reactivity with the PA
ELISA in contrast to other gram-positive bacteria containing
LTA or lipomannan or gram-negative bacteria containing LPS
(Table 1; Fig. 3). ELISA reactivity was clearly shown to be
associated with bacterial lipoglycans containing a -1,5-ga-
lactofuranosyl chain. Only a few bifidobacterial lipoglycans
have been structurally analyzed, but also other bifidobacterial
species seem to contain reactive residues in their cell wall (7,
18, 30). This specific epitope can be detected as a surface
antigen, shown by the reactivity of the suspended cell pellet,
but also as an exoantigen, shown by the reactivity of the cell-
free supernatant of a liquid culture (Table 3). Secretion of
lipoglycans during normal growth was already shown by Op
den Camp et al. with B. bifidum subsp. pennsylvanicum (33).
The complete removal of PA ELISA reactivity after deacyla-
tion of the supernatant, compared to the 50% decrease with
GM, suggests that only the acylated micellar form reacts in the
PA ELISA.
When our results were extrapolated to the neonatal host, a
calculation was made to estimate the PA ELISA reactivity of
feces as potential source of cross-reactivity in the neonate. The
bifidobacterial numbers found in feces (15, 29) are very high,
and the EI per gram of feces is also high, ranging from 4,000 to
100,000. In order to confirm this calculation, FISH analysis was
performed on neonatal fecal samples with a genus-specific
probe for bifidobacteria. This 16S rRNA hybridization tech-
nique is a fast method to quantify bifidobacteria in the human
gut (21). The presence of bifidobacteria was associated with
PA ELISA reactivity of the fecal samples, but reactivity
showed some variation, which probably depends on the bi-
fidobacterial species present, as shown by the calculated exam-
ples. The results clearly show that the bifidobacterial commu-
nity in the gut is a significant source of PA ELISA reactivity
and that, considering the dilution in the blood volume, the
serum concentration could become high enough after trans-
mucosal passage to be detected with the PA ELISA. Further-
more, false-positive PA reactivity in fully breast-fed neonates
could not come from galactomannan since breast milk reacts
negatively in the PA ELISA (results not shown).
E. lenta is, like Bifidobacterium species, a gram-positive,
obligatory anaerobic, non-spore-forming rod and has been
found in adult feces at concentrations of 108.5 cells/g, in 4 out
of 12 subjects that were tested (detection limit, 107 cells/g)
(41). Furthermore, the number increased in the intestinal mi-
croflora of healthy subjects after administration of antibacte-
rial agents (32). Comparable species have also been found in
feces of children at 109.6 cells/g, but the bacteria were not
identified to species level (15, 29). So, in addition to Bifidobac-
terium, this species might also form an important source of PA
ELISA reactivity in the intestine. Since E. lenta is present in
the fecal flora of adults, it might also be a cause of false PA
ELISA serum reactivity in adults. Recently developed species-
specific oligonucleotide probes might be helpful with future
studies of E. lenta in the human intestine (19, 41).
Positivity of fecal samples has already been shown (1) but
was always correlated with consumption of food containing
fungal GM from contaminated sources (1, 23). In addition to
the host’s own microflora as a source of bifidobacteria, ELISA
reactivity of certain food products is more likely to result from
bifidobacterial lipoglycan than from fungal GM. Because of
their health-promoting effects, bifidobacteria are widely used
as probiotics and food additives and are present in fermented
foods like milk, olives, sauerkraut, yogurt, butter, and cheese
(3). Especially B. lactis and Bifidobacterium animalis are often
used, and amounts of 107 to 108 of bifidobacteria per gram of
food can be found (20, 40, 50). As can be seen in Fig. 3, B. lactis
(recently reclassified as a subspecies of B. animalis [50]) and B.
animalis show high reactivities and could act as a source of
ELISA serum reactivity after consumption of food products.
Furthermore, bifidobacteria are used as fecal indicator organ-
isms and have been found on meat and meat products and in
raw milk (2, 11). Especially meat products are often GM pos-
itive (23) but are more likely contaminated with bifidobacteria
instead of fungal GM.
The frequent isolation of bifidobacteria from clinical infec-
tions in recent years has raised debate whether the bacteria are
actually infective (3, 17, 36). However, even if there’s a lack of
pathogenicity in immunocompromised patients (3), bifidobac-
teria can invade the host by bacterial translocation (17). This
phenomenon is caused by a diminished intestinal barrier, re-
sulting in the passage of bacteria or bacterial components or
products across the mucous membrane and epithelium. Not
only intestinal mucosal injury by for instance cytotoxic chemo-
therapy or an immature intestinal mucosa but also immuno-
TABLE 3. PA ELISA reactivity of liquid RCM cultures of
B. bifidum subsp. pennsylvanicum
Sample EIa (n 	 2) Recovery (%)
Total culture 62.1 100
Cell-free supernatant 23.5 37.8
Suspended cell pellet 16.0 25.8
a Sample EI was corrected for dilution (20 to 40), and cell pellet values are
also corrected for the five-fold concentration step (from 1,000 l to 200 l)
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deficiency in the host, overgrowth of intestinal bacteria, and
treatment with antibiotics and/or immunosuppressive agents
have been shown to promote translocation of intestinal bacte-
ria (i.e., bifidobacteria) (6, 17). The actual translocation of
reactive components across the intestinal wall remains to be
proven but seems even more likely for an exocellular lipogly-
can molecule of 10 kDa. Penicillin treatment of B. bifidum
subsp. pennsylvanicum resulted in an increase of lipoglycan
excretion (33). This was not the result of bacteriolysis, as was
also observed for acylated or deacylated LTAs of other bacte-
ria and for other inhibitors of cell wall synthesis (33, 35, 43, 49).
Consequently, antibiotic treatment of immunocompromised
patients will increase the free lipoglycan pool in the intestine
which may easily translocate to the blood.
In the blood, lipoglycan might bind to different components,
resulting in a mixture of Galf-containing molecules that react
in the PA ELISA, as is the case with GM (27). LTAs and
lipoglycans spontaneously bind to mammalian cell membranes.
In a study on B. bifidum subsp. pennsylvanicum it was shown
that its lipoglycan bound reversibly to human colonocytes (8.3
 108 binding sites/cell) and erythrocytes (2.1  106 binding
sites/cell) (34). The lipid part of the molecule was shown to be
responsible for binding. Furthermore, the lipoglycan of B. bi-
fidum subsp. pennsylvanicum exhibited strong binding to the
macrophage scavenger receptor, comparable to the LTA of
Staphylococcus aureus (13). In order to analyze the nature and
structure of the cross-reacting molecule(s) present in (false-)
positive serum samples, a method is needed that specifically
isolates reactive components because of their small amounts
present. Several techniques (28) can then be used for further
analysis to discriminate between false- and true-positive PA
ELISA results and thereby prevent unnecessary preemptive
treatment of patients.
The Bifidobacterium lipoglycan offers an explanation for the
occurrence of a high rate of false PA ELISA reactivity among
neonates and infants. Furthermore, together with E. lenta,
these bacteria might also be the cause of false-positive reac-
tivity in adult patients.
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